Day: April 13, 2022

Top-line Data Scheduled to Report in Q2 2022 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 13, 2022 – Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that patient enrollment has been completed in its Phase 2a clinical study evaluating dipraglurant as a potential treatment for blepharospasm, a type of dystonia characterized by involuntary contractions or spasms of the eyelid muscles. Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5 (mGlu5) through allosteric modulation to downregulate the neurotransmission believed to cause blepharospasm. A total of 15 patients have been enrolled into this double-blind, placebo controlled Phase 2a feasibility study. The...

Press ReleaseRegulated Information13 April 2022, 7:00 am CET, Antwerp, Belgium   The shareholders of VGP NV (the “Company”) are hereby invited to attend the annual shareholders’ meeting and the extraordinary and special shareholders’ meeting (the “Meetings”) which shall consecutively take place at Botanic Sanctuary Antwerp (room Amaryllis), Leopoldstraat 26, 2000 Antwerp, Belgium, on Friday 13 May 2022 at 10:00 am. Please consult the website link: www.vgpparks.eu/en/investors/shareholder-meetings/ for further information concerning the agenda, admission conditions and voting modalities for the Meetings. The board of directors CONTACT DETAILS FOR INVESTORS AND MEDIA ENQUIRIESInvestor Relations Tel: +32 (0)3 289 1433investor.relations@vgpparks.euPetra Vanclova (External Communications) Tel: +42 602 262 107  ABOUT VGP VGP is a...

Amsterdam, April 13, 2022: Arcadis (EURONEXT: ARCAD) – Water pipes in parts of South Yorkshire in the UK could be used to speed up the roll-out of faster broadband without digging up roads, under UK Government plans to trial innovative new technology to boost digital connectivity across the country. This ground-breaking project, delivered by Yorkshire Water working with Arcadis and University of Strathclyde, will test solutions involving putting fibre sensors inside the water pipes. The first trial of its kind in the UK, it will also explore how fibre can help the water industry detect and repair leaks, often before they cause a problem for consumers. This will help water companies operate more efficiently and lower the carbon cost of drinking water. Under the proposals, fibre-optic cables would be deployed through 17 kilometres...

Basel, Switzerland, April 13, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, reported today that promising preclinical data on the anti-cancer activity of its three oncology drug candidates, BAL0891, derazantinib and lisavanbulin, have been presented at the Annual Meeting of the American Association for Cancer Research (AACR) that took place April 8-13, 2022, in New Orleans, USA. BAL0891 is a potential first-in-class mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division leading to tumor cell death. A first poster showed in-vitro data on the activity of BAL0891 against its targets, threonine tyrosine kinase (TTK) and polo-like-kinase 1 (PLK1). The activity of BAL0891 led to a faster disruption...

Mowi ASA (OSE:MOWI): Q1 2022 Trading update Harvest volumes Q1 2022 (1)Farming Norway 59.5 thousand tonnesFarming Scotland 10.5 thousand tonnesFarming Chile 16.0 thousand tonnesFarming Canada 9.0 thousand tonnesFarming Ireland 1.0 thousand tonnesFarming Faroes 1.0 thousand tonnesTotal 97.0 thousand tonnes   In connection with the presentation of the Q4 2021 results, Mowi ASA guided a total harvest volume of 98 thousand tonnes (GWE) for Q1 2022. Note:(1) The harvest volumes are provided in gutted weight equivalents (GWE). Additional information Operational EBIT for the Group was approximately EUR 207 million in Q1 2022 (EUR 109 million in Q1 2021). Blended Farming cost per kg harvested was EUR 4.77. Total Operational EBIT per kg through the value chain was approximately as follows:Norway EUR 2.55Scotland EUR 1.00Chile EUR 1.25Canada EUR 2.55  Ireland EUR 3.70Faroes EUR 1.50     Operational...

Stellantis to Consolidate Financial Services in ChinaCompany intends to consolidate its auto financial services in China into a Stellantis wholly owned Auto Finance Company (AFC) Stellantis and DPCA stake in DPCAFC, the 15–year-old auto finance joint venture between Stellantis, DPCA and Dongfeng Group, will be sold to Dongfeng, subject to regulatory approval New structure will align with Dare Forward 2030 ‘asset light business model’ in China and support the new DPCA business modelAMSTERDAM, April 13, 2022 – Following the restructuring of financial services in Europe and the United States, Stellantis today announced PSA Finance Nederland (PFN), a fully owned financing subsidiary of BPF (Banque PSA Finance), and DPCA have entered into an equity transfer agreement with Dongfeng Group, on the basis of which their respective...

SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today the pricing of an underwritten follow-on offering of 5,625,563 shares of its common stock at a price to the public of $22.22 per share. All of the shares to be sold in the offering are to be sold by Crinetics. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $125.0 million. The offering is expected to close on or about April 18, 2022, subject to the satisfaction of customary closing conditions. Crinetics intends to use the...

LA JOLLA, Calif., April 12, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the Phase 2 clinical trial of MN-166 (ibudilast) in hospitalized COVID-19 patients at risk for developing acute respiratory distress syndrome (ARDS) has completed enrollment. Kazuko Matsuda, MD, PhD, MPH, Chief Medical Officer of MediciNova, Inc., commented, “The last enrolled patient’s last visit has been completed. We plan to report the top line efficacy results after the data cleaning process is completed for the database lock.” About the Clinical Trial This study was a multi-center, randomized (1:1), double-blind, placebo-controlled, parallel-group study of MN-166 (ibudilast)...

NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES Toronto, ON, Canada , April 12, 2022 (GLOBE NEWSWIRE) — Canada Carbon Inc. (the “Company“) (TSX-V : CCB) is pleased to announce a non-brokered private placement of up to 16,000,000 units (each, a “Unit”) at a price of $0.075 per Unit (the “Issue Price”) for aggregate gross proceeds of up to $1,200,000 (the “Offering”). Each Unit shall be comprised of one common share (each, a “Common Share”) in the capital of the Company and one common share purchase warrant (each, a “Warrant”). Each Warrant shall entitle the holder thereof to acquire one Common Share at a price of $0.9375 per Common Share for a period of 60 months from the date of issuance. The Company expects to close the Offering by the end of April, 2022. “As Canada Carbon embarks on an effort to expand...

HEIDELBERG, Germany, April 12, 2022 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the pricing of its previously announced public offering of 22,500,000 of its common shares at a public offering price of $4.00 per common share. In addition, Affimed has granted the underwriters a 30-day over-allotment option to purchase up to 3,375,000 common shares at the public offering price less underwriting discounts. After deducting the underwriting discounts, the net proceeds of the public offering are expected to be $84.6 million. The offering is expected to close on or about April 18, 2022, subject to customary closing conditions. Jefferies LLC, SVB Leerink, Truist Securities, Inc....